Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the period of September 2022, specifically reporting on events occurring on September 9, 2022. The filing announces the presentation of initial Phase 1 clinical data for IMC-F106C, an off-the-shelf ImmTAC targeting PRAME, at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and corporate announcements rather than financial performance.
Material Changes and Clinical Results
The primary material update concerns the Phase 1 portion of the IMC-F106C-101 trial in patients with multiple solid tumor cancers. As of the data cut-off date of July 18, 2022:
- Patient Enrollment: 55 patients treated across 10 dose cohorts.
- Safety Profile: The drug was well-tolerated. The most frequent treatment-related adverse event was cytokine release syndrome (CRS), which was mostly Grade 1, with no events greater than Grade 3. No treatment discontinuations or deaths were attributed to related adverse events.
- Biological Activity: Doses greater than 20 mcg demonstrated clinical activity with consistent interferon gamma induction. Retrospective analysis showed high PRAME expression in the majority of patients.
- Efficacy: Durable partial responses (PR) were observed in:
- 2 patients with cutaneous melanoma (out of 6 enrolled).
- 2 patients with ovarian cancer (out of 4 enrolled).
- 3 patients with tebentafusp-naive uveal melanoma (out of 6 enrolled).
- Response Duration: Six of the seven partial responses were ongoing, with two patients maintaining PR for over seven months.
- Negative Findings: No partial responses were observed in uveal melanoma patients who had progressed on prior tebentafusp.
Outlook, Risks, and Management Commentary
Management highlighted the robust T-cell activation markers and the durability of responses in specific tumor types. The company hosted a virtual investor event to discuss these data points. The filing notes that the website and related presentation materials are not incorporated into the report. No specific financial guidance or forward-looking financial projections were included in this text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) for detailed statistical tables not summarized here.
- Confirm the specific tumor types and prior treatment histories for the 10 additional efficacy-evaluable patients who did not achieve partial responses.
- Review the company's latest Form 20-F or quarterly reports for current cash runway and burn rate, as this filing contains no financial data.
- Monitor upcoming regulatory filings for the transition of IMC-F106C from Phase 1 to Phase 2 expansion cohorts.